Evidence map›Paper›PMID 30858165›Full record

ArticleMolecular pharmacology2019

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.

Nicole L Michmerhuizen, Elizabeth Leonard, Chloe Matovina, Micah Harris, Gabrielle Herbst, Aditi Kulkarni, Jingyi Zhai, Hui Jiang, Thomas E Carey, J Chad Brenner

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.Journal of neurological surgery. Part B, Skull base · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Nicole L MichmerhuizenDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Elizabeth LeonardDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Chloe MatovinaDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Micah HarrisDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Gabrielle HerbstDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Aditi KulkarniDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Jingyi ZhaiDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Hui JiangDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
Thomas E CareyDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan.
J Chad BrennerDepartments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology-Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan chadbren@umich.edu.
University of Michigan–Ann Arbor · US

Funding

Dissecting Co-Dependent Pathways in Oral CancersU01DE025184 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENNER, JOHN CHADWICK, CAREY, THOMAS E. · 2015 to 2018
$3.7M
Molecular Mechanisms of Tumor Behavior and Response to Therapy in HPV-positive Oropharyngeal CancerR01CA194536 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CAREY, THOMAS E. · 2016 to 2021
$2.8M
NCI NIH HHS R01 CA194536NIDCR NIH HHS U01 DE025184
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of cancer characterized by poor patient outcomes and low survival rates. In HNSCC, genetic aberrations in phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR) pathway genes are common, and small molecules targeting these pathways have shown modest effects as monotherapies in patients. Whereas emerging preclinical data support the combined use of PI3K and EGFR inhibitors in HNSCC, in-human studies have displayed limited clinical success so far. Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics. We confirmed the efficacy of PI3K and EGFR combination therapies, observing synergy with

Indexed as

Phosphoinositide-3 Kinase InhibitorsAfatinibCell Line, TumorEnzyme InhibitorsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsGefitinibHead and Neck NeoplasmsHumansProtein Kinase InhibitorsPyridinesQuinazolinesSignal TransductionSquamous Cell Carcinoma of Head and NeckSulfonamides2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamideAfatinibEGFR protein, humanEnzyme InhibitorsErb-b2 Receptor Tyrosine KinasesErbB Receptorsethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo(1,2-a)pyridine-3-carboxylateGefitinibPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPyridinesQuinazolinesSulfonamides

Identifiers

PMID30858165
PMCPMC6442321
OpenAlexW2920961693

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.